RLFTF Stock: Relief Therapeutics affirms Zyesami COVID-19 trial, gains momentum

Shares of Relief Therapeutics (OTC:RLFTF) has gained momentum again as the company affirms Zyesami COVID-19 trial. Together with it’s partner NeuroRx, these companies have breakthrough treatments for the COVID-19 coronavirus.

According to the press release the company has affirmed the Zyesami trial in COVID-19 patients. The stock is starting to gain momentum on it’s promising drug.

Furthermore, topline data for it’s IV trial is expected to be released this month, however, the statistical analysis of the data remains ongoing. Relief expects top-line data from this trial to be reported once the required statistical analyses have been completed.

Last week the company partnered with Acer Therapeutics for distribution, this could be a good sign. If the company continues to enter into numerous distribution agreements with other companies it could up it’s profit line.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button